An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust

Bhagawati-Prasad V.; Aspden E.; Chan S.; Darby A.

首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust

【24h】

An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust

机译：约克教学医院和Harrogate and District NHS Foundation Trust对具有EGFR激活突变的NSCLC患者使用一线EGFR TKI治疗的审计

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Lung cancer: Journal of the International Association for the Study of Lung Cancer》 |2016年第1期|共2页
作者
Bhagawati-Prasad V.; Aspden E.; Chan S.; Darby A.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust [J] . Bhagawati-Prasad V., Aspden E., Chan S., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2016,第Suppla1期

机译：约克教学医院和Harrogate and District NHS Foundation Trust对具有EGFR激活突变的NSCLC患者使用一线EGFR TKI治疗的审计
2. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs [J] . Brueckl Wolfgang, Tufman Amanda, Huber Rudolf Maria Expert review of anticancer therapy . 2017,第1a6期

机译：具有激活EGFR突变的先进的非小细胞肺癌（NSCLC）：用AFATINIB和其他EGFR TKI的一线治疗
3. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism [J] . Liu Sangtian, He Yayi, Jiang Tao, Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2018,第期

机译：EGFR-TKIS PLUS化疗在EGFR-TKIS中表现出优越的疗效，作为EGFR突变和BIM缺失多态性的先进NSCLC患者的一线设置。
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. First-Generation EGFR-TKI Plus Chemotherapy Versus EGFR-TKI Alone as First-Line Treatment in Advanced NSCLC With EGFR Activating Mutation: A Systematic Review and Meta-Analysis of Randomized Controlled Trials [O] . Qiang Wu, Wuxia Luo, Wen Li, 2021

机译：第一代EGFR-TKI加上化疗与EGFR-TKI单独作为高级NSCLC的一线治疗具有EGFR激活突变：随机对照试验的系统评价和荟萃分析
6. First-generation EGFR-TKI plus chemotherapy versus EGFR-TKI alone as first-line treatment in advanced NSCLC with EGFR activating mutation: a systematic review and meta-analysis of randomized controlled trials [O] . Qiang Wu, Wuxia Luo, Wen Li, 2020

机译：第一代EGFR-TKI加上化疗与EGFR-TKI单独作为高级NSCLC的一线治疗，具有EGFR激活突变：随机对照试验的系统评价和荟萃分析

An audit of the use of first-line EGFR TKI treatment in NSCLC patients with EGFR activating mutations at the York Teaching Hospitals and Harrogate and District NHS Foundation Trust

著录项

引文网络

相似文献

相关主题

期刊订阅